Abstract:

Cancer is a common disease and radiotherapy is one well-established treatment for some solid tumours. Hyperbaric oxygenation therapy (HBOT) may improve the ability of radiotherapy to kill hypoxic cancer cells, so the administration of radiotherapy while breathing hyperbaric oxygen may result in a reduction in mortality and recurrence. To assess the benefits and harms of administering radiotherapy for the treatment of malignant tumours while breathing HBO. In September 2017 we searched the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Library Issue 8, 2017, MEDLINE, Embase, and the Database of Randomised Trials in Hyperbaric Medicine using the same strategies used in 2011 and 2015, and examined the reference lists of included articles. Randomised and quasi-randomised studies comparing the outcome of malignant tumours following radiation therapy while breathing HBO versus air or an alternative sensitising agent.

Bennett, Feldmeier, Smee, Milross (2018). Hyperbaric oxygenation for tumour sensitisation to radiotherapy. The Cochrane database of systematic reviews, 2018 04;4():CD005007. https://www.ncbi.nlm.nih.gov/pubmed/29637538